Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 92 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Intestinal Failure Clear all
Approved For Marketing No phase listed Expanded access

Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children

NCT02328768
View directory record Official record
Conditions
Total Parenteral Nutrition-Induced Cholestasis
Interventions
Omegaven
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia

NCT03326583
View directory record Official record
Conditions
ESRD, Hyperkalemia, End Stage Renal Disease
Interventions
Patiromer
Drug
Lead sponsor
Dominic Raj
Other
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Jul 22, 2026, 5:03 AM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Not applicable Interventional

Chyme Reinfusion for Type 2 Intestinal Failure

NCT04577456
View directory record Official record
Conditions
Intestinal Failure, Enterocutaneous Fistula, Ileostomy - Stoma, High Output Stoma
Interventions
The Insides System
Device
Lead sponsor
The Insides Company
Industry
Eligibility
21 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Gainesville, Florida • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Jul 22, 2026, 5:03 AM EDT
Completed No phase listed Observational

Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition

NCT05011370
View directory record Official record
Conditions
Intestinal Failure-associated Liver Disease
Interventions
Not listed
Lead sponsor
Protara Therapeutics
Industry
Eligibility
12 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Kissimmee, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Not applicable Interventional

Prebiotics in Peritoneal Dialysis

NCT03265639
View directory record Official record
Conditions
End Stage Renal Disease, Gut Microbiome Dysbiosis
Interventions
P-inulin
Dietary Supplement
Lead sponsor
Ali Ramezani
Other
Eligibility
21 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2018 · Synced Jul 22, 2026, 5:03 AM EDT
Terminated Phase 2 Interventional Results available

Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan

NCT01004159
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cetuximab with irinotecan
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

NCT01103323
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Regorafenib (Stivarga, BAY73-4506), Placebo, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
26
States / cities
Beverly Hills, California • Los Angeles, California • Mission Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Not applicable Interventional

Food Preparation Effects on Gut Bacteria in Patients on Peritoneal Dialysis

NCT02467530
View directory record Official record
Conditions
End Stage Renal Disease (ESRD)
Interventions
AGE
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Jul 22, 2026, 5:03 AM EDT
No Longer Available No phase listed Expanded access

Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis

NCT02148146
View directory record Official record
Conditions
Cholestasis
Interventions
Omegaven
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Jul 22, 2026, 5:03 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Chronic Kidney Disease in Relation to Alterations in Protein and Amino Acid Metabolism and Function

NCT01890811
View directory record Official record
Conditions
Chronic Kidney Failure
Interventions
Boost High Protein
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
55 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Jul 22, 2026, 5:03 AM EDT
Recruiting Not applicable Interventional

AI-driven Total Parenteral Nutrition Platform

NCT07414576
View directory record Official record
Conditions
Intestinal Failure
Interventions
AI-driven total parenteral nutrition (TPN)
Device
Lead sponsor
Takeoff41, Inc.
Industry
Eligibility
Up to 6 Months
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 22, 2026, 5:03 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer

NCT00838578
View directory record Official record
Conditions
Colorectal Cancer
Interventions
KRN330, Irinotecan
Biological · Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
12
States / cities
Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Jul 22, 2026, 5:03 AM EDT
Withdrawn Early Phase 1 Interventional

Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease

NCT02738905
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Rifaximin
Drug
Lead sponsor
Jason Stubbs, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Kansas City, Kansas • Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Jul 22, 2026, 5:03 AM EDT
Completed No phase listed Observational

Low Dose Irradiation for Small Bowel Transplant

NCT00382486
View directory record Official record
Conditions
Irreversible Intestinal Failure, Allograft Rejection
Interventions
Reduce the risk of allograft rejection
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
17 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2007 · Synced Jul 22, 2026, 5:03 AM EDT
Approved For Marketing No phase listed Expanded access

Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage

NCT01861834
View directory record Official record
Conditions
Cholestasis of Parenteral Nutrition
Interventions
Omegaven 10%
Drug
Lead sponsor
Georgetown University
Other
Eligibility
2 Months to 18 Years
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Phase 3 Interventional

Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF

NCT04627025
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
apraglutide
Drug
Lead sponsor
VectivBio AG
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Los Angeles, California • Naples, Florida • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Jul 22, 2026, 5:03 AM EDT
Completed No phase listed Observational

Genomics, Single Nucleotide Polymorphisms (SNPs), and Clinical Neonatology

NCT00315263
View directory record Official record
Conditions
Lung Disease, Brain Injury, Necrotizing Enterocolitis, Respiratory Failure
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 25, 2011 · Synced Jul 22, 2026, 5:03 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

The Role of Gut Microbiota in Heart Failure and Pre-Heart Failure With Preserved Ejection Fraction

NCT02728154
View directory record Official record
Conditions
Heart Failure
Interventions
Blood Sample, Stool Sample
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Jul 22, 2026, 5:03 AM EDT
Recruiting No phase listed Observational

Familial Investigations of Childhood Cancer Predisposition

NCT03050268
View directory record Official record
Conditions
Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2037
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Phase 4 Interventional Results available

Antifungal Locks to Treat Fungal-related Central Line Infections

NCT00936910
View directory record Official record
Conditions
Central Line Fungal Infections
Interventions
amphotericin B liposomal (Ambisome)
Drug
Lead sponsor
Bill McGhee
Other
Eligibility
30 Days to 21 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Jul 22, 2026, 5:03 AM EDT
Completed Phase 1 Interventional

Oral Fecal Transplant in Cirrhosis

NCT03152188
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Liver
Interventions
FMT, Placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Jul 22, 2026, 5:03 AM EDT
Completed No phase listed Observational

Kids Intestinal Dysfunction in Congenital Heart Disease: the Kind Heart Study

NCT02824705
View directory record Official record
Conditions
Congenital Disease
Interventions
Congenital Heart Disease Surgery
Procedure
Lead sponsor
University of Arizona
Other
Eligibility
3 Days to 2 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Jul 22, 2026, 5:03 AM EDT